The Scottish Medicines Consortium has accepted Iluvien for prevention of relapse in recurrent noninfectious posterior segment uveitis, Alimera announced in a press release.
The decision was based on a cost-utility analysis of the PSV-FAI-001 clinical study, which compared Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) with standard treatment, including systemic corticosteroids or immunosuppressants, topical steroids, intraocular pressure reduction therapy, cataract removal and other elective ocular surgical procedures, according to the release.
“We continue to execute on
Uncategorized